Literature DB >> 20447956

Stable bone mineral density in lumbar spine and hip in contrast to bone loss in the hands during long-term treatment with infliximab in patients with rheumatoid arthritis.

Danielle A Eekman, Marijn Vis, Irene E M Bultink, Dirk J Kuik, Alexandre E Voskuyl, Ben A C Dijkmans, Willem F Lems.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20447956     DOI： 10.1136/ard.2009.127787

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  24 in total

Review 1.  Skeletal complications of rheumatoid arthritis.

Authors:  L Heinlen; M B Humphrey
Journal:  Osteoporos Int       Date:  2017-08-04       Impact factor: 4.507

2.  Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: a population-based cohort study.

Authors:  Seo Young Kim; Sebastian Schneeweiss; Jun Liu; Daniel H Solomon
Journal:  J Bone Miner Res       Date:  2012-04       Impact factor: 6.741

3.  Infliximab improves bone metabolism and bone mineral density in rheumatoid arthritis and ankylosing spondylitis: a prospective 2-year study.

Authors:  Gabriel Dischereit; Ingo H Tarner; Ulf Müller-Ladner; Uwe Lange
Journal:  Clin Rheumatol       Date:  2012-11-24       Impact factor: 2.980

Review 4.  Effects of anti-tumor necrosis factor α agents on bone.

Authors:  Vivian K Kawai; C Michael Stein; Daniel S Perrien; Marie R Griffin
Journal:  Curr Opin Rheumatol       Date:  2012-09       Impact factor: 5.006

Review 5.  Current Treatments and New Developments in the Management of Glucocorticoid-induced Osteoporosis.

Authors:  Hennie G Raterman; Irene E M Bultink; Willem F Lems
Journal:  Drugs       Date:  2019-07       Impact factor: 9.546

Review 6.  Can bone loss in rheumatoid arthritis be prevented?

Authors:  M Vis; M Güler-Yüksel; W F Lems
Journal:  Osteoporos Int       Date:  2013-06-18       Impact factor: 4.507

7.  Biologic disease-modifying anti-rheumatic drugs and the risk of non-vertebral osteoporotic fractures in patients with rheumatoid arthritis aged 50 years and over.

Authors:  J-P Roussy; L Bessette; S Bernatsky; E Rahme; J Lachaine
Journal:  Osteoporos Int       Date:  2013-03-16       Impact factor: 4.507

Review 8.  Osteoporosis drug therapy strategies in the setting of disease-modifying agents for autoimmune disease.

Authors:  B F Ricciardi; J Paul; A Kim; L A Russell; J M Lane
Journal:  Osteoporos Int       Date:  2012-09-07       Impact factor: 4.507

9.  Biologicals and bone loss.

Authors:  Charlotte L M Krieckaert; Willem F Lems
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-08       Impact factor: 5.346

10.  Paradoxical elevation of serum TRACP5b levels despite increase in lumbar spine bone mineral density during anti-TNFα therapy in patients with inflammatory rheumatic disease: a 2-year prospective assessment of bone mass, bone metabolism, and the trabecular bone score.

Authors:  Éric Toussirot; Laurent Mourot; Barbara Dehecq; Fabrice Michel; Daniel Wendling; Émilie Grandclément; Gilles Dumoulin
Journal:  Eur J Rheumatol       Date:  2017-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.